Vanda Pharmaceuticals' NEREUS™ Gains FDA Approval for Motion Sickness Prevention
TL;DR Summary
Vanda Pharmaceuticals received FDA approval for NEREUS (tradipitant), the first new drug in over 40 years for preventing motion sickness-induced vomiting, supported by robust clinical trial data showing significant efficacy and safety, marking a major advancement in treatment options for this condition affecting millions.
- Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness PR Newswire
- VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains Yahoo Finance
- Stock Movers: Vanda, Nike, Year in Review Bloomberg.com
- US FDA approves Vanda Pharmaceuticals' motion sickness drug Reuters
- Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin Seeking Alpha
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
8 min
vs 9 min read
Condensed
97%
1,601 → 44 words
Want the full story? Read the original article
Read on PR Newswire